Pharmacy Services: Roles Within the US Healthcare System

Pharmacy services occupy a regulated, clinically active position within the US healthcare system — bridging the prescribing authority of licensed practitioners with the safe dispensing and monitoring of medications for patients across all care settings. This page covers the definition and scope of pharmacy practice, the operational mechanisms governing dispensing and counseling, common service scenarios across retail, hospital, and specialty contexts, and the regulatory decision boundaries that define professional roles. Understanding how pharmacy services function is essential context for navigating the US healthcare system broadly and for interpreting how types of medical providers collaborate in patient care.

Definition and scope

Pharmacy services encompass the preparation, dispensing, review, and monitoring of medications, as well as patient education and collaborative drug therapy management. In the United States, pharmacy practice is regulated at the state level through individual boards of pharmacy, while federal oversight is maintained by the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) for controlled substances under the Controlled Substances Act (21 U.S.C. § 801 et seq.).

The National Association of Boards of Pharmacy (NABP) provides model practice standards and administers licensure examinations, including the NAPLEX (North American Pharmacist Licensure Examination). As of the 2023 NABP Survey of Pharmacy Law, all 50 states plus the District of Columbia require pharmacists to hold a Doctor of Pharmacy (Pharm.D.) degree and pass standardized licensing examinations before practicing.

Pharmacy services are classified across four principal settings:

1. Retail/community pharmacy — outpatient dispensing, over-the-counter medication guidance, immunizations, and medication therapy management (MTM)
2. Hospital/institutional pharmacy — inpatient compounding, IV preparation, formulary management, and clinical pharmacist consultations within interdisciplinary teams
3. Specialty pharmacy — management of high-cost, complex biologics, oncology agents, and medications requiring special handling or patient monitoring programs
4. Mail-order/pharmacy benefit management (PBM) pharmacy — high-volume dispensing of maintenance medications coordinated through insurance benefit structures

Pharmacy technicians operate under pharmacist supervision in all settings, with technician registration or certification required in 48 states (PTCB State Regulations Map).

How it works

The dispensing process follows a defined sequence regardless of setting. A licensed prescriber — physician, nurse practitioner, physician assistant, or dentist, depending on state scope-of-practice laws — generates a prescription. That prescription is transmitted electronically via an e-prescribing platform (required for controlled substances in 32 states under individual state mandates) or delivered in written form.

Upon receipt, the pharmacy workflow proceeds through these phases:

1. Prescription intake and data entry — patient demographics, drug name, strength, quantity, and prescriber verification are entered into the dispensing system
2. Drug utilization review (DUR) — automated screening for drug-drug interactions, allergy conflicts, duplicate therapy, and dose range errors, as required under Omnibus Budget Reconciliation Act of 1990 (OBRA '90) provisions (CMS OBRA '90 guidance)
3. Insurance adjudication — claims are processed in real time through the patient's pharmacy benefit; prior authorization may be required for certain high-cost or restricted drugs
4. Dispensing and verification — a pharmacist performs final verification of the filled prescription before release
5. Patient counseling — OBRA '90 mandates an offer to counsel for Medicaid patients; most state boards extend this to all patients

Specialty pharmacy adds a layer of Risk Evaluation and Mitigation Strategies (REMS), which the FDA requires for 68 drugs or drug categories with serious safety risks (FDA REMS database). REMS programs may require prescriber enrollment, patient registries, or dispensing only through certified pharmacies.

Chronic disease management programs increasingly embed clinical pharmacists in care teams, where collaborative practice agreements (CPAs) allow pharmacists to adjust medication doses, order labs, and manage specific disease states under physician oversight — a model recognized in all 50 states but with widely varying scope.

Common scenarios

Retail prescription dispensing represents the highest-volume pharmacy function. The National Council for Prescription Drug Programs (NCPDP) reports that US pharmacies fill approximately 4 billion prescriptions annually. Retail pharmacists routinely screen for interactions in patients managing hypertension, diabetes, or hyperlipidemia on 5 or more concurrent medications — a clinical condition called polypharmacy, which affects an estimated 40% of adults aged 65 and older according to data published in the Journal of the American Geriatrics Society.

Immunization administration has expanded steadily since the 1990s. As of 2024, pharmacists hold immunization authority in all 50 states under CDC and state health department frameworks (CDC Pharmacy-Based Immunization Delivery). This connects pharmacy services directly to preventive care and wellness services.

340B drug pricing applies to covered outpatient entities — including federally qualified health centers and qualifying hospitals — allowing purchase of outpatient drugs at reduced costs. The Health Resources and Services Administration (HRSA) administers the 340B program, which covered more than 50,000 pharmacy sites as of HRSA's 2023 program data.

Long-term care (LTC) pharmacy services nursing facilities and assisted living settings with unit-dose packaging, consultant pharmacist reviews, and regulatory compliance support under CMS Conditions of Participation (42 CFR § 483.45).

Decision boundaries

Pharmacy practice is bounded by clear professional and legal demarcations that distinguish it from prescribing authority and from medical diagnosis.

Pharmacist vs. prescriber authority: Pharmacists dispense, counsel, and — under CPAs — adjust therapy within defined protocols. They do not independently diagnose conditions or initiate new therapeutic categories outside an established CPA. The DEA Schedule classification system (21 CFR § 1308) restricts controlled substance dispensing to prescriptions from DEA-registered practitioners; Schedule II drugs require a written or electronic prescription and prohibit refills.

Retail vs. specialty pharmacy: Retail pharmacies may not dispense certain REMS-restricted drugs unless the pharmacy itself is certified in the applicable REMS program. This creates a defined boundary: a standard chain pharmacy cannot fill a REMS-restricted oncology agent without program enrollment.

Compounding boundaries: The Drug Quality and Security Act of 2013 (DQSA, Pub. L. 113-54) established two compounding categories — 503A (patient-specific, licensed pharmacy) and 503B (outsourcing facilities producing large batches). 503B facilities are registered with the FDA and subject to Current Good Manufacturing Practice (cGMP) standards; 503A pharmacies are not, but face state board oversight.

Telepharmacy operates under state-specific statutes. As of the NABP 2023 survey, 43 states have enacted telepharmacy statutes or regulations, allowing remote verification by a licensed pharmacist for dispensing at satellite locations — a development with direct implications for rural healthcare access.

Medical billing and coding basics for pharmacy services operate primarily through NCPDP transaction standards rather than the ICD-10 or CPT code sets used in physician billing, a structural distinction that affects how pharmacy claims are processed and audited differently from medical claims.

References

• U.S. Drug Enforcement Administration — Controlled Substances Act (21 U.S.C. § 801)
• National Association of Boards of Pharmacy (NABP)
• Pharmacy Technician Certification Board (PTCB) — State Regulations
• FDA — Risk Evaluation and Mitigation Strategies (REMS)
• Centers for Medicare & Medicaid Services (CMS) — OBRA '90
• Health Resources and Services Administration (HRSA) — 340B Drug Pricing Program
• Electronic Code of Federal Regulations — 42 CFR § 483.45 (Pharmacy Services, LTC)
• Electronic Code of Federal Regulations — 21 CFR § 1308 (DEA Schedules)
• FDA — Drug Quality and Security Act (DQSA)
• CDC — Pharmacy-Based Immunization Delivery
• [National Council for Prescription Drug Programs (NCPDP)](https://